EUCTR2018-003650-24-GB进行中（未招募）1 期
A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has reached the primary completion endpoint or the main data analysis, or has been stopped prematurely.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Participant must be age-eligible in the feeder study at the time of signing the informed consent.
- •Type of Participant and Disease Characteristics
- •2. Participant is currently participating in any Bayer-sponsored regorafenib study and is receiving study treatment.
- •3. Participant is currently benefiting from treatment with regorafenib monotherapy and meets criteria to initiate a subsequent cycle of therapy, as determined by the guidelines of the feeder protocol.
- •4. Any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption by the investigator.
- •5. Male or female
- •Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. This applies for the time between signing of the informed consent form and 2 months after the last administration of the study intervention.
- •Male participants:
- •In addition to the above methods, male trial participants and male partners of female trial participants must also use condoms during sex as an extra measure of protection against pregnancy.
- •Female participants:
- •The investigator or a designated associate is requested to advise sexually active participants on how to achieve highly effective birth control using one or more of the following methods:
- •Hormonal contraception associated with inhibition of ovulation containing both estrogen and progestogen (oral, intravaginal or transdermal)
- •Hormonal contraception associated with inhibition of ovulation containing only progestogen (oral, injectable or implantable)
- •Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
- •Bilateral tubal occlusion
- •Vasectomized partner (provided that partner is the sole sexual partner of the woman of childbearing potential who is the trial participant and that the vasectomized partner has received medical assessment of surgical success)
- •Women not considered to be of childbearing potential include those who biologically sterile, permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or postmenopausal. Postmenopausal women are defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
- •Informed Consent
- •6. Capable of giving signed informed consent as described in Appendix 1 (Section 10.1) which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
排除标准
- •Medical Conditions
- •1. Ineligibility, for medical reasons, to start the next cycle in the respective feeder study
- •2. Patients with a beta-hCG test consistent with pregnancy.
- •Prior/Concomitant Therapy
- •3. Participants are using one or more of the prohibited medications listed in the respective feeder study protocol. A comprehensive list can be found in Section 6.4.
- •Prior/Concurrent Clinical Study Experience
- •4. Participant has been previously permanently discontinued from regorafenib treatment.
- •Diagnostic assessments
- •Not Applicable for this study.
- •Other Exclusions
- •5. Participant is unable to comply with the requirements of the study.
研究者
相似试验
已完成
4 期
A clinical study of regorafenib in participants who have been treated in previous Bayer-sponsored regorafenib studies that have been completedhepatocellular carcinomaJPRN-jRCT1080224680Bayer Yakuhin, Ltd.50
进行中（未招募）
1 期
Regorafenib rollover study1.metastatic or unresectable renal cell cancer (RCC)2.metastatic and/or unresectable gastrointestinal stromal tumors (GIST)3.metastatic colorectal cancer (CRC)4.hepatocellular carcinoma (HCC)MedDRA version: 21.1Level: LLTClassification code 10038407Term: Renal cell cancerSystem Organ Class: 100000004864EUCTR2018-003650-24-ITBAYER AG15
进行中（未招募）
1 期
Regorafenib rollover studyEUCTR2018-003650-24-DEBayer AG15
招募中
2 期
Regorafenib rollover studySolid TumorsJPRN-jRCT2031230602Tanigawa Takahiko1
已完成
2 期
A Phase 2 Multicenter, Open-label, Single-arm Study of KTE-C19 in Japanese Patients with Refractory or Relapsed Large B Cell LymphomaRefractory or relapsed (relapse after transplant or relapse after medication in patients ineligible for transplant) diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), transformed follicular lymphoma (TFL) or High-grade B cell lymphomaJPRN-jRCT1080223858Gilead Sciences K.K.10